Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission

Published:February 21, 2015DOI:


      • There is a decline of daily insulin dose after euglycemia achieved.
      • The decrement of daily insulin dose is related to reduction of insulin resistance during the therapy.
      • Patients with lowest decline of insulin dose had higher risk of hyperglycemic relapse.



      To investigate the insulin requirement profiles during short-term intensive continuous subcutaneous insulin infusion (CSII) in patients with newly diagnosed type 2 diabetes and its relationship with long-term glycemic remission.


      CSII was applied in 104 patients with newly diagnosed type 2 diabetes. Daily insulin doses were titrated and recorded to achieve and maintain euglycemia for 2 weeks. Measurements of blood glucose, lipid profiles as well as intravenous glucose tolerance tests were performed before and after the therapy. Afterwards, patients were followed up for 1 year.


      Total daily insulin dose (TDD) was 56.6 ± 16.1 IU at the first day when euglycemia was achieved (TDD-1). Thereafter, TDD progressively decreased at a rate of 1.4 ± 1.0 IU/day to 36.2 ± 16.5 IU at the end of the therapy. TDD-1 could be estimated with body weight, FPG, triglyceride and waist circumference in a multiple linear regression model. Decrement of TDD after euglycemia was achieved (ΔTDD) was associated with reduction of HOMA-IR (r = 0.27, P = 0.008) but not with improvement in β cell function. Patients in the lower tertile of ΔTDD had a significantly higher risk of hyperglycemia relapse than those in the upper tertile within 1 year (HR 3.4, 95%CI [1.4, 8.4], P = 0.008).


      There is a steady decline of TDD after euglycemia is achieved in patients with newly diagnosed type 2 diabetes treated with CSII, and ΔTDD is associated with a better long-term glycemic outcome.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Xu Y.
        • Wang L.
        • He J.
        • Bi Y.
        • Li M.
        • Wang T.
        • et al.
        Prevalence and control of diabetes in Chinese adults.
        JAMA. 2013; 310: 948-959
        • UK Prospective Diabetes Study (UKPDS) Group
        Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
        Lancet. 1998; 352: 854-865
        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • Matthews D.R.
        • Neil H.A.
        10-Year follow-up of intensive glucose control in type 2 diabetes.
        N Engl J Med. 2008; 359: 1577-1589
        • Kahn S.E.
        • Haffner S.M.
        • Heise M.A.
        • Herman W.H.
        • Holman R.R.
        • Jones N.P.
        • et al.
        Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
        N Engl J Med. 2006; 355: 2427-2443
        • Li Y.
        • Xu W.
        • Liao Z.
        • Yao B.
        • Chen X.
        • Huang Z.
        • et al.
        Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.
        Diabetes Care. 2004; 27: 2597-2602
        • Son J.W.
        • Jeong H.K.
        • Lee S.S.
        • Kim S.R.
        • Cha B.Y.
        • Son H.Y.
        • et al.
        The Effect of early intensive insulin therapy on body fat distribution and beta-cell function in newly diagnosed type 2 diabetes.
        Endocr Res. 2013; 38: 160-167
        • Weng J.
        • Li Y.
        • Xu W.
        • Shi L.
        • Zhang Q.
        • Zhu D.
        • et al.
        Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
        Lancet. 2008; 371: 1753-1760
        • Hu Y.
        • Li L.
        • Xu Y.
        • Yu T.
        • Tong G.
        • Huang H.
        • et al.
        Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission.
        Diabetes Care. 2011; 34: 1848-1853
        • Kramer C.K.
        • Zinman B.
        • Retnakaran R.
        Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis.
        Lancet Diabetes Endocrinol. 2013; 1: 28-34
      1. Chinese guidline for type 2 diabetes—2013. Chin J Diabetes Mellitus 2014; 6:447–498,

        • Liu J.
        • Liu J.
        • Fang D.
        • Liu L.
        • Huang Z.
        • Wan X.
        • et al.
        Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients.
        Endocr J. 2013; 60: 725-732
        • Liu L.
        • Wan X.
        • Liu J.
        • Huang Z.
        • Cao X.
        • Li Y.
        Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.
        Diabetes Technol Ther. 2012; 14: 756-761
        • Xu W.
        • Li Y.B.
        • Deng W.P.
        • Hao Y.T.
        • Weng J.P.
        Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study.
        Chin Med J (Engl). 2009; 122: 2554-2559
        • Huang Z.
        • Wan X.
        • Liu J.
        • Deng W.
        • Chen A.
        • Liu L.
        • et al.
        Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
        Diabetes Technol Ther. 2013; 15: 859-869
        • WHO
        Definition, diagnosis and classifications of diabetes mellitus and its complications.
        Report of a WHO consultation, Part 1: Diagnosis and classification of diabetes mellitus. 1999
        • Noh Y.H.
        • Lee W.J.
        • Kim K.A.
        • Lim I.
        • Lee J.H.
        • Lee J.H.
        • et al.
        Insulin requirement profiles of patients with type 2 diabetes after achieving stabilized glycemic control with short-term continuous subcutaneous insulin infusion.
        Diabetes Technol Ther. 2010; 12: 271-281
        • Gao G.Q.
        • Dong Q.Y.
        • Li S.J.
        • Zhang Y.Y.
        • Li W.X.
        • Du W.H.
        • et al.
        Investigation of the insulin dose and characteristics of continuous subcutaneous insulin infusion in Chinese people with type 2 diabetes.
        Diabetes Technol Ther. 2011; 13: 1135-1138
        • Cai X.
        • Han X.
        • Luo Y.
        • Ji L.
        Analysis of insulin doses of Chinese type 2 diabetic patients with intensive insulin treatment.
        PLoS ONE. 2012; 7: e38962
        • Kuroda A.
        • Kaneto H.
        • Yasuda T.
        • Matsuhisa M.
        • Miyashita K.
        • Fujiki N.
        • et al.
        Basal insulin requirement is ∼30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump.
        Diabetes Care. 2011; 34: 1089-1090
        • Yang W.
        • Liu J.
        • Shan Z.
        • Tian H.
        • Zhou Z.
        • Ji Q.
        • et al.
        Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
        Lancet Diabetes Endocrinol. 2014; 2: 46-55
        • Papa G.
        • Baratta R.
        • Cali V.
        • Degano C.
        • Iurato M.P.
        • Licciardello C.
        • et al.
        Factors that influence basal insulin requirement in type 2 diabetes.
        Acta Diabetol. 2012; 49: 387-393
        • Wittlin S.D.
        Treating the spectrum of type 2 diabetes: emphasis on insulin pump therapy.
        Diabetes Educ. 2006; 32: 39S-46S
        • Nathan D.M.
        • Buse J.B.
        • Davidson M.B.
        • Ferrannini E.
        • Holman R.R.
        • Sherwin R.
        • et al.
        Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2009; 32: 193-203
        • Chibalin A.V.
        • Leng Y.
        • Vieira E.
        • Krook A.
        • Bjornholm M.
        • Long Y.C.
        • et al.
        Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance.
        Cell. 2008; 132: 375-386
        • Tang S.
        • Le-Tien H.
        • Goldstein B.J.
        • Shin P.
        • Lai R.
        • Fantus I.G.
        Decreased in situ insulin receptor dephosphorylation in hyperglycemia-induced insulin resistance in rat adipocytes.
        Diabetes. 2001; 50: 83-90
        • Kim M.K.
        • Jang E.H.
        • Son J.W.
        • Kwon H.S.
        • Baek K.H.
        • Lee K.W.
        • et al.
        Visceral obesity is a better predictor than generalized obesity for basal insulin requirement at the initiation of insulin therapy in patients with type 2 diabetes.
        Diabetes Res Clin Pract. 2011; 93: 174-178
        • Biesenbach G.
        • Raml A.
        • Alsaraji N.
        Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI.
        Diabetes Obes Metab. 2006; 8: 669-673
        • Chen A.
        • Huang Z.
        • Wan X.
        • Deng W.
        • Wu J.
        • Li L.
        • et al.
        Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment.
        Diabetes Care. 2012; 35: 474-481
        • Bhattacharya S.
        • Ammini A.C.
        • Jyotsna V.
        • Gupta N.
        • Dwivedi S.
        Recovery of beta-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients.
        Diabetes Technol Ther. 2011; 13: 461-465
        • Harrison L.B.
        • Adams-Huet B.
        • Li X.
        • Raskin P.
        • Lingvay I.
        Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial.
        J Investig Med. 2014; 62: 676-686